Adverse outcomes (death, cardiac transplantation, and ventricular-assist device placement) occurred in 30% of patients.
Therapeutic management (invasive and non-invasive ventilation, nutrition support) and clinical outcomes (death, length of stay) were similar between groups.
The model allows predicting outcomes (death, HF hospitalization, NYHA class distribution) up to 5 years with distinctive analysis time points at 1, 2, 3 and 4 years.
Patients were further categorized according to two different outcomes: death at day 30, or a combined outcome of death and/or admission to ICU during the follow-up of day 30.
We systematically assessed the predictive performance of this method for major clinical outcomes (death, metastasis, recurrence, response to therapy) and the correlation of gene profiling with other clinicopathological correlates of malignant disorders.
To assess the impact of clinical instability (CI) and delirium on admission to a rehabilitation unit on clinical and functional outcomes (death, transfer to acute care, poor functional recovery) at discharge, in a population of elderly patients.
To compare the abilities of six validated comorbidity indices (Charlson index, cumulative illness rating scale [CIRS], index of coexistent diseases, Kaplan scale, geriatrics index of comorbidity [GIC], and chronic disease score) to predict adverse hospitalization outcomes (death during hospitalization, length of stay, and institutionalization).
But three different state trials resulted in the same unfair outcomes: death for those that did not physically participate in the killings, and life for those who did.
Accordingly, we examined the prognostic values of PFT abnormalities in the CD28% High cohort to assess whether this subpopulation could be further stratified for risks of adverse clinical outcomes (death or lung transplantation).
Admission outcomes (death or discharge) were recorded.
Clinical outcomes (death or resolution) were recorded for all patients.
